IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤Cash $14.0 million as of September 30, 2026, versus $10.7 million prior year
- ➤Net loss $4.6 million, or $0.24 per share, versus $3.9 million
- ➤INB-619 initial in vivo preclinical data remains on track by year-end 2026
- ➤IN8bio appointed Oxana Polyakova, Ph.D., Senior Vice President of R&D
- ➤R&D expenses rose to $2.6 million, driven primarily by TCE platform costs
Expert Statements
William Ho, CEO and co-founder of IN8bio
“This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform.”
William Ho, CEO and co-founder of IN8bio
“It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, “may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs” as stated in the Nature Reviews article.”
William Ho, CEO and co-founder of IN8bio
“We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end.”
* Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development * Received third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune disease * Remain on track to report initial in vivo (animal) data for INB-619 by year-end 2026 NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the third quarter ended September 30, 2026.
“This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform,” said William Ho, CEO and co-founder of IN8bio. “It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, “may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs” as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end.”
Get started
Create a free account to read the full story.